Improvement with 1 week of treatment with transcranial direct current stimulation is sustained for 12 weeks.
Because negative symptoms of schizophrenia have been associated with low activity in the prefrontal cortex (PFC), researchers in a sham-controlled, Brazilian study examined the effects of transcranial direct current stimulation (tDCS) in 95 schizophrenia patients with prominent negative symptoms. The device is commercially available but does not have FDA approval.
Código de aprobación: PP-MHP-PEB-0009
Portal web de Pfizer para Profesionales, donde podrá acceder a una amplia variedad de contenidos y servicios tales como:
Confirmo que soy profesional de la salud residente en Perú.
Si no es profesional de la salud consulte
www.pfizer.com.pe